Updated 14:15 GMT, 21 Nov 2026 SPX 6,910.39 -3.70% NDX 25,028.98 -5.61% VIX 35.89 +26.20% GOLD 3,515.40 -4.62% CL 83.98 +0.93% BTC 60,166.89 +2.33%
NAS100 25,029 −5.61% S&P 6,910 −3.70% GOLD $3,515 −4.62% BTC $60,167 +2.33% VIX 35.89 +26.20% latest tape · as of 14:15 UTC
The Screen · Healthcare · Biotechnology

Forte Biosciences Inc

FBRX · NASDAQ · USD · Market cap $1.6B · 22 employees

Forte Biosciences, Inc.

FAIL · Does not pass the screen
76.99 USD

Price as of 19 Nov 2026Daily close, not a live quote

Screened 2026-11-19 · the tape above runs as of 14:15 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed

Key facts today

  • Price76.99 USD at the 19 Nov 2026 close
  • Our value readFair vs our fair value, as of 19 Nov 2026
  • Our regime readAccumulation, as of 15 Nov 2026
  • Ethical screenDoes not pass
  • Last reviewed19 Nov 2026 (2 days ago)
  • Release timesRelease and earnings times on your chart: Event Guard Mentor

A summary of the dated readings below, not a live quote and not advice.

PRICE · ONE YEAR

Our fair-value range: $61.00 to $77.00, base estimate $77.00 (screen dated 2026-11-19).

Current read
Accumulation ?
Fair · screened 2026-11-19
  • Trend Accumulation
  • Insiders no filings inside 60 days, left as found
  • Positioning no disclosures inside 60 days, left as found
  • Options no verdict drawn today, left as found
  • Ethical does not pass the values gate
Price76.99 USD
Fair value77.00
Ethical score70.0/100
Value readFairas of 19 Nov 2026
Our investment reviews on this name
2026-08-28Read Accumulation76.86+0.2% to today ✓Markdown gives way to Accumulation after a 338% rise in 8 weeks
2026-07-02Read Markdown17.56+338.4% to today First review on file: Markdown

Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.

The full research record, in depth, below
The Label · The Season, Not the Day

This name holds its accumulation label.

Forte Biosciences Inc holds its Accumulation at $76.99. Elevated stress, defensive posture warranted, held for 11 days.

As held on the ledger · 2026-11-19
PhaseAccumulation
Quantitative stateElevated stress, defensive posture warranted, held for 11 days
Price at the screen$76.99
ValuationN/A trailing · -18.89 forward price to earnings
Values screenFAIL · score 70.0
Beta2.65
The Workings

Five Screens: FBRX's Results

FAIL. Accounts receivable

TestFigureLimitStatus
Business activity Permissible Permissible core business Pass
Debt load Excluded Below 33% Fail
Interest-bearing cash 0.00% Below 33% Pass
Receivables 93.95% Below 49% Fail

Definitions, sources and threshold rules: ticker values-screen methodology.

The Ethical Read

Why It Falls Short, in Plain English

Forte Biosciences's business is fine, but its receivables are about 94% of its assets, well over the ~49% line, so it does not pass on the financial screens.

Read as at 20 Nov 2026. It updates when the underlying figures move, and past reads are kept below. How we screen.

Follow this verdict

Get an email when FBRX's ethical verdict changes

Today FBRX does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.

Free, no account needed. Every email has a link to stop.

What the Numbers Say It Is Worth

The Fair Value Range

Our analysis reads Fair to fair value, as of 19 Nov 2026: it trades at roughly a 0% discount to our $77.00 fair value, none competitive moat.

Method.

61.00Conservative77.00Base case77.00Growth case 76.99Price

USD, 2026-11-19 screen. A 0.0% under base.

The Street's Range
61.00Street low 77.00Street average 77.00Street high 76.99Price

Street: 4 covering, consensus Buy. Average target +0%.

Chart
The Business, in Plain Words

Clinical stage biotech with no revenue or moat

Picture a lab racing to turn one antibody into a treatment for several autoimmune diseases, yet still years from any sales. Forte Biosciences sits in exactly that spot. The shares trade below our fair value estimate, analysts like the story, and the ethical screen raises no flags, yet the opportunity rating stays at none because the business has no moat, no profits, and negative returns on equity of 188 percent.

Forward earnings sit at a negative 11.8 times while the profit margin remains zero. The lead candidate, FB-102, targets CD122 but has yet to prove itself in large trials. Without recurring revenue or pricing power, any upside rests on binary clinical results rather than steady cash flow.

Risk sits around the usual biotech trap of repeated capital raises and trial setbacks that can wipe out value quickly. Even a clean ethical pass cannot offset the absence of a durable business. Analysis, not advice.

The fundamentals · plain-English read
Forward P/E-18.9x
EPS, trailing-4.57
EPS, forward-4.08
Profit margin0.0%currently unprofitable
Return on equity-62.3%not currently earning a positive return on equity
FCF yield-2.53%
Current ratio10.01comfortably covers its short-term bills
Beta2.65much more volatile than the market
Short interest, float0.08%
52-week range10.11 - 77.20
MoatNONE
Market cap$1.6B
Employees22

FBRX-specific watchpoints · The things to watch: it's a small-cap, so the share price can swing harder than the market; it already moves more than the market on an average day; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.

Metric definitions and interpretation rules: ticker-page methodology.

The Dated Journal · Newest First, Never Edited

Every Entry, As Written

2026-11-20 Accumulation $76.99 +0.0% Entry 17
2026-11-09 Accumulation $76.99 +0.0% Entry 16
2026-11-08 Accumulation $76.99 +0.0% Entry 15
2026-11-07 Accumulation $76.99 +0.0% Entry 14
2026-11-06 Accumulation $76.99 +0.0% Entry 13
2026-11-05 Accumulation $76.99 +0.0% Entry 12
2026-11-04 Accumulation $76.99 +0.0% Entry 11
2026-11-03 Accumulation $76.99 +0.0% Entry 10
2026-11-02 Accumulation $76.99 +0.0% Entry 9

Earnings landed in this window.

2026-10-30 Accumulation $76.99 +0.0% Entry 8

Ethical screening: FAIL.

Written on its date, before the outcome; never pruned.

Latest News · What the Market Is Reading on FBRX

Headlines from third-party outlets, linked for reference: not our reporting, not advice.

Related Securities · Others in FBRX's Space

Screened names in the same industry · explore each on its own page.

What Holding Actually Paid · Price Plus Dividends
If $1,000 had been placed · historical, not a promise
PeriodPrice thenPrice returnDivs per share$1,000 becameTotal return
1 month $26.00 -35.5% · $645 -35.5%
2 months $35.09 -52.2% · $478 -52.2%
3 months $27.12 -38.2% · $618 -38.2%
6 months $22.65 -26.0% · $740 -26.0%
1 year $12.25 +36.9% · $1,369 +36.9%
2 years $13.75 +22.0% · $1,220 +22.0%
3 years $24.80 -32.4% · $676 -32.4%
5 years $1,020.50 -98.4% · $16 -98.4%

Historical returns from market close data. Past performance does not guarantee future results.

The Ledger's Promise

This entry now belongs to the ledger. Whatever FBRX does next, these words stay.

Forte Biosciences Inc · FBRX · Accumulation · $76.99
Recorded 2026-11-19 · before the outcome · scored mechanically

Membership

Thirteen thousand names carry this page. One desk keeps them honest.

Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.

Join the desk

Screening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.

Get our weekly market brief free.